

- Think Ethics Programme need to review the benefits. Key risk around Information and Consent public involvement requirement.
- Recovery Resilience and Growth delays to some activities due to re-prioritisation.


Forward look


- Research Systems Programme procurement being revisited. IRAS Website NHSX assessment date TBC (dependency on content planning). Interim infrastructure work underway including disaster recovery.
- Think Ethics Programme benefits to be redefined by end Oct. Intermediate benefits to be reviewed at Oct PDG.
- Recovery Resilience and Growth -. ECMC pilot webinar in Oct. People centred data collection to begin.
- Streamlining Data Driven Research Complete. Closure and Lessons Learned reports to come to Oct PDG.
- Corporate Information Management SharePoint audit report expected in October. Business Case process to be signed off in October.
- UK Clinical Trials Legislation planning to continue through October and remaining resources to be allocated.


Benefits realisation


· All required realisation plans in place.


CODE	NAME	PM	SRO	ВСМ	STRATEGIC OBJECTIVE	FINISH DATE	соѕт	TIME	RISKS	BENEFITS	OVERALL RAG
X00602	Research Systems Programme	Cl	JW	?	2/3/4	31/03/25	£5,833k		20 (1)		
P098	Think Ethics Programme	SE/IA	JFB	NB	1/2	31/03/23	£124k		20 (1) 🗼		
P092	Streamlining Data Driven Research	SM	ВР	SB/PM/ZK	2/3	30/09/22	£468k				
P103	Recovery Resilience and Growth	KGr	JM	JFB	1/2	31/03/23	£513k	↓			↓
P049	Corporate Information Management	IH	ST	TS	3/4	31/03/23	£98k				
P104	UK Clinical Trials Legislation	JD	SB	MH/NY/JH/?	1/2/3/4	31/03/23					













RRG Programmes & Projects On track Delay / risk of delay in non critical activities Work the HRA is leading on but is already reported in the Delay / risk of delay in critical activity or dependency Dependency main Portfolio Plan on slides 2 & 3 11/11/2022 2022/23 Q3 (Oct-Dec) Q4 (Jan-Mar) Q1 (Apr-Jun) Q2 (Jul-Sep) IRAS website public Beta & IRAS Development (RSP) **UK Clinical Trials Regulations Guidance & Implementation (UK Clinical Trials Legislation) New approaches to Participant Information (Think Ethics)**





RAG Status Definitions

	Green	Amber	Red
Cost	Within 10% +/-	Within 10% - 20% +/-	Over 20% +/- (unable to recover)
Time	On track	Delay in non critical activities	Delay in critical activity or dependency
Risks	tbc re. risk appetite	tbc re. risk appetite	tbc re. risk appetite
Benefits	Benefits profiles and benefits realisation plan signed off, on benefits register	 Benefits in process of being defined Benefits defined but not signed off Benefits need reviewing 	 Benefits not defined / no benefits identified Benefits no longer valid